Donal McLornan

Featured in: Favicon

nature.com Favicon

science.org Favicon

thelancet.com Favicon

futuremedicine.com Favicon

medicinejournal.co.uk Favicon

onlinelibrary.wiley.com

Articles

Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison | Bone Marrow Transplantation

Feb 20, 2024 | nature.com | Dietrich Wilhelm Beelen |Friedrich Stölzel |Fabio Ciceri |Wolfgang Andreas Bethge |Peter Dreger |Donal McLornan | +2 more

AbstractA randomized study (acronym: MC-FludT.14/L Trial II) demonstrated that fludarabine plus treosulfan (30 g/m²) was an effective and well tolerated conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →